Status: Recruiting
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
Participants needed: 40
Trial details
Phase: Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: Cybrexa TherapeuticsUpdated: Oct 6, 2025Locations: 17
Eligibility criteria
Subjects who have received only 1 platinum-based chemotherapy regimen for at lea... [+7]
Cytotoxic chemotherapy, biologic agent, investigational agent, or radiation ther... [+4]